Pietro Merli1, Mattia Algeri1, Francesca Del Bufalo1, Franco Locatelli2,3. 1. Department of Pediatric Hematology and Oncology, Bambino Gesù Children's Hospital, Piazza Sant'Onofrio, 4, 00165, Rome, Italy. 2. Department of Pediatric Hematology and Oncology, Bambino Gesù Children's Hospital, Piazza Sant'Onofrio, 4, 00165, Rome, Italy. franco.locatelli@opbg.net. 3. Sapienza University of Rome, Rome, Italy. franco.locatelli@opbg.net.
Abstract
PURPOSE OF REVIEW: The remarkable improvement in the prognosis of children with acute lymphoblastic leukemia (ALL) has been mainly achieved through the administration of risk-adapted therapy, including allogeneic hematopoietic stem cell transplantation (HSCT). This paper reviews the current indications to HSCT in ALL children, as well as the type of donor and conditioning regimens commonly used. Finally, it will focus on future challenges in immunotherapy. RECENT FINDINGS: As our comprehension of disease-specific risk factors improves, indications to HSCT continue to evolve. Future studies will answer the year-old question on the best conditioning regimen to be used in this setting, while a recent randomized controlled study fixed the optimal anti-thymocyte globulin dose in unrelated donor HSCT. HSCT, the oldest immunotherapy used in clinical practice, still represents the gold standard consolidation treatment for a number of pediatric patients with high-risk/relapsed ALL. New immunotherapies hold the promise of further improving outcomes in this setting.
PURPOSE OF REVIEW: The remarkable improvement in the prognosis of children with acute lymphoblastic leukemia (ALL) has been mainly achieved through the administration of risk-adapted therapy, including allogeneic hematopoietic stem cell transplantation (HSCT). This paper reviews the current indications to HSCT in ALL children, as well as the type of donor and conditioning regimens commonly used. Finally, it will focus on future challenges in immunotherapy. RECENT FINDINGS: As our comprehension of disease-specific risk factors improves, indications to HSCT continue to evolve. Future studies will answer the year-old question on the best conditioning regimen to be used in this setting, while a recent randomized controlled study fixed the optimal anti-thymocyte globulin dose in unrelated donor HSCT. HSCT, the oldest immunotherapy used in clinical practice, still represents the gold standard consolidation treatment for a number of pediatric patients with high-risk/relapsed ALL. New immunotherapies hold the promise of further improving outcomes in this setting.
Authors: Charles G Mullighan; Sima Jeha; Deqing Pei; Debbie Payne-Turner; Elaine Coustan-Smith; Kathryn G Roberts; Esmé Waanders; John K Choi; Xiaotu Ma; Susana C Raimondi; Yiping Fan; Wenjian Yang; Guangchun Song; Jun J Yang; Hiroto Inaba; James R Downing; Wing H Leung; W Paul Bowman; Mary V Relling; William E Evans; Jinghui Zhang; Dario Campana; Ching-Hon Pui Journal: Blood Date: 2015-11-02 Impact factor: 22.113
Authors: Koji Sasaki; Elias J Jabbour; Farhad Ravandi; Nicholas J Short; Deborah A Thomas; Guillermo Garcia-Manero; Naval G Daver; Tapan M Kadia; Marina Y Konopleva; Nitin Jain; Ghayas C Issa; Vicki Jeanis; Haim G Moore; Rebecca S Garris; Naveen Pemmaraju; Jorge E Cortes; Susan M O'Brien; Hagop M Kantarjian Journal: Cancer Date: 2016-08-01 Impact factor: 6.860
Authors: M A Pulsipher; B Langholz; D A Wall; K R Schultz; N Bunin; W Carroll; E Raetz; S Gardner; R K Goyal; J Gastier-Foster; M Borowitz; D Teachey; S A Grupp Journal: Bone Marrow Transplant Date: 2015-05-11 Impact factor: 5.483
Authors: V Rocha; J Cornish; E L Sievers; A Filipovich; F Locatelli; C Peters; M Remberger; G Michel; W Arcese; S Dallorso; K Tiedemann; A Busca; K W Chan; S Kato; J Ortega; M Vowels; A Zander; G Souillet; A Oakill; A Woolfrey; A L Pay; A Green; F Garnier; I Ionescu; P Wernet; G Sirchia; P Rubinstein; S Chevret; E Gluckman Journal: Blood Date: 2001-05-15 Impact factor: 22.113
Authors: Isaac Yaniv; Aviva C Krauss; Eric Beohou; Arnaud Dalissier; Selim Corbacioglu; Marco Zecca; Boris V Afanasyev; Massimo Berger; Miguel Angel Diaz; Krzysztof Kalwak; Petr Sedlacek; Stefania Varotto; Christina Peters; Peter Bader Journal: Biol Blood Marrow Transplant Date: 2018-03-13 Impact factor: 5.742
Authors: Shannon L Maude; Theodore W Laetsch; Jochen Buechner; Susana Rives; Michael Boyer; Henrique Bittencourt; Peter Bader; Michael R Verneris; Heather E Stefanski; Gary D Myers; Muna Qayed; Barbara De Moerloose; Hidefumi Hiramatsu; Krysta Schlis; Kara L Davis; Paul L Martin; Eneida R Nemecek; Gregory A Yanik; Christina Peters; Andre Baruchel; Nicolas Boissel; Francoise Mechinaud; Adriana Balduzzi; Joerg Krueger; Carl H June; Bruce L Levine; Patricia Wood; Tetiana Taran; Mimi Leung; Karen T Mueller; Yiyun Zhang; Kapildeb Sen; David Lebwohl; Michael A Pulsipher; Stephan A Grupp Journal: N Engl J Med Date: 2018-02-01 Impact factor: 91.245
Authors: E Coustan-Smith; A Gajjar; N Hijiya; B I Razzouk; R C Ribeiro; G K Rivera; J E Rubnitz; J T Sandlund; M Andreansky; M L Hancock; C-H Pui; D Campana Journal: Leukemia Date: 2004-03 Impact factor: 11.528
Authors: Sascha Lieber; Victoria Ruscher; Jörn-Sven Kühl; Johannes Schulte; Markus Blankenburg; Tobias Reindl; Pablo Hernáiz Driever Journal: J Cancer Res Clin Oncol Date: 2020-04-28 Impact factor: 4.553
Authors: Ellen Fraint; Bianca A Ulloa; María Feliz Norberto; Kathryn S Potts; Teresa V Bowman Journal: Stem Cells Transl Med Date: 2020-10-15 Impact factor: 6.940